tirzepatide cardiovascular outcomes trial 2024 American Heart Association Scientific Sessions has started off with a bang! Results are in for the SUMMIT study: Treatment with (Mounjaro/ Zepbound) was associated with 38% ⬇️ in combined risk Tirzepatide as Compared with Semaglutide
Description
Mechanisms by which GLP-1RAs may alter gallbladder function GLP-1RAs, although beneficial for metabolic control, appear to influence gallbladder function through several mechanisms that may increase the risk of biliary disease (Figure 2)
Experiencing side effects is not required for Mounjaro to be effective
American Diabetes Association
The escalation schedule is not rigid
The combination of these mechanics means the practical refund amount - if you qualify - may be significantly less than your total spending over the 24-week period
